Ranbaxy Innovation and Growth Focus

Key Financial Numbers and Ratios Past financial performance 4 yr ($ Mn) 2009 2010 2011 2012 CAGR Net Sales 1,519 1,868 2,112 2,310 15% EBITDA 121 402 335 353 42% EBITDA Margin 8% 22% 16% 15% EBT from ordinary activities 131 399 218 288 30% EBT from ordinary activities as a % of sales 9% 21% 10% 12% R&D Expense 98 127 104 93 R&D Expense/Sales% 6% 7% 5% 4% Debt/Equity Ratio 1.6 1.3 1.5 1.1 RANBAXY Trusted medicines.Healthier lives 28

View entire presentation